J&J suing Samsung Bioepis over Stelara biosimilar
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
GlobalData on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...
Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.
Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...
Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback